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Objective: In young children with asthmatic symptoms diagnostic difficulties lead to use of tri-
als of asthmamedication as a diagnostic tool. Our aim is to quantify the persistent use of asthma
medication, initiated in the first year of life and identify determinants of this persistent use.
Patients and methods: We identified 165 children within the PIAMA (Prevention and Incidence
of Asthma and Mite Allergy) birth cohort who used asthma medication before the age of one.
Persistent use was investigated during three years after the first prescription. A Cox regression
analysis was performed to identify factors associated with persistent use.
Results: A total of 58.8% of children continued using asthma medication after the first prescrip-
tion and 10.3% continued during three years. Children with doctor-diagnosed asthma (Hazard0 274 3830; fax: þ31 30 274 4407.
H.A. Smit).
8 Elsevier Ltd. All rights reserved.
Persistence of asthma medication use 1447ratio of discontinuation (HR)Z 0.64, 95% CI: 0.45e0.91) or prescribed inhaled corticosteroids in
the first year of life (HR of discontinuationZ 0.59, 95% CI: 0.40e0.86) were 1.6e1.7 times more
likely to continue using asthma medication.
Conclusions: Persistence of asthma medication, prescribed in the first year of life is very low
and is positively associated with doctor-diagnosed asthma and use of inhaled corticosteroids.
Characterizing persistent users of asthma medication is important to understand prescribing
of asthma medication in this age group.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
When a preschool child with symptoms suggestive of
asthma presents at the physician’s office, a diagnosis of
asthma cannot be made with confidence. 1e4 It is well
known that wheezing at a young age may not only be due
to asthma but also to other, more transient, respiratory
conditions. 2e6 Only a minority of wheezing children will de-
velop persistent symptoms and will, therefore, be diag-
nosed as having asthma.7e10 However, despite this
diagnostic uncertainty, asthma medication is often pre-
scribed to wheezing infants. Moreover, the response to
asthma medication itself is widely used as a diagnostic
tool to strengthen or reject the possible diagnosis of
asthma.3,5,11,12 The GINA guidelines state that ‘a trial of
asthma medication is probably the most confident way to
make a diagnosis on asthma in children’.11 The rationale
behind the trial treatment is that young children with
wheezing but no underlying asthmatic disease are expected
not to respond to treatment and will, therefore, discon-
tinue treatment after evaluation of the effect. It is not
known how often infants initiating such trial treatment
benefit from the asthma medication and, therefore, con-
tinue medication use.13 Notwithstanding the fact that
asthmatic symptoms over time influence persistence of
medication use, some patient characteristics, already
known at start of asthma medication therapy, might be
predictive of persistent asthma medication use in preschool
children. If so, this could aid the decision whether or not to
start a trial of asthma medication in a preschool child. The
objective of this study is to quantify persistence of use of
asthma medication in preschool children and identify possi-
ble determinants of persistence of use, which can be as-
sessed at start of therapy.
Methods
Study design and study population
For this study we identified 165 children from the PIAMA
(Prevention and Incidence of Asthma and Mite Allergy)
study, who received asthma medication before the age of
one.
The PIAMA study is a prospective birth cohort study
among 4146 children. The design of the PIAMA study has
been described in detail elsewhere.14 In short, the partici-
pating children are born between July 1996 and October
1997. They were recruited from the general population
through prenatal healthcare clinics in three different re-
gions of the Netherlands. Data on respiratory and allergicsymptoms, potential risk factors for asthma and allergy
and demographic factors were collected by postal question-
naires. Parents were sent a questionnaire during the last
trimester of pregnancy, at the child’s age of three months
and annually thereafter. Longitudinal data on medication
use have been collected at age four through prescription
data from community pharmacy records. In the Nether-
lands, pharmacy records are virtually complete with regard
to drugs dispensed to patients.15
Asthma medication and persistence of use
Medical drug prescriptions were registered according to the
Anatomical Therapeutic Chemical (ATC) Classification sys-
tem.16 All medicines with ATC code R03 were considered to
be asthma medication: inhaled short acting b2-agonists
(SABA), oral short acting b2-agonists, inhaled long acting
b2-agonists (LABA), inhaled corticosteroids (ICS), inhaled
cromones, anticholinergics and montelukast. Oral cortico-
steroids (H02AB) were not classified as primary asthma
treatment. Persistence of use of asthma medication was
investigated during a time-window of three years, using
discontinuation rates.17 The index date was defined as
the date of the first prescription for asthma medication.
Discontinuation of treatment was defined as the occurrence
of a treatment gap of more than 365 days between one dis-
pensing of asthma medication and a subsequent dispensing
during the study time-window. Time to discontinuation was
calculated as the number of days from the index date to the
date of the last dispensing before the gap of more than 365
daysþ a pre-specified time period of 90 days (which is the
maximum duration of a single prescription in the
Netherlands).
A wide treatment gap of 365 days is chosen because we
want to quantify the amount of children receiving an initial
prescription for asthma medication without needing asthma
medication regularly over the next couple of years and
compare these children with the ones who might still have
intermittent or seasonal complaints but do return to use of
asthma medication at least once every year. If the aim had
been to determine continuing availability of asthma
medication the allowed treatment gap would have been
much smaller.Statistical analysis
Persistence of use was examined using survival analysis, the
endpoint being discontinuation of asthma medication. The
overall persistence of use was determined using Kaplane
Meier analyses. Univariate and multivariate Cox regression
Table 1 General characteristics of the study population:
children receiving asthma medication in the 1st year of life.
Patient characteristics (nZ 165)
Sex, % boysb 69.7
Mean age at end of follow-up, yrs (SD) 3.6 (0.19)
Mother’s educational level, %c,f
Low 23.0
Intermediate 44.2
High 32.7
Father’s educational level, %c,f
Low 24.7
Intermediate 39.5
High 35.8
Ethnicity, % Dutchd 94.6
Any other siblings, %c 70.9
Allergic sibling(s), %c 33.9
Allergic mother, %a 32.1
Allergic father, %b 37.5
Parental asthma, %a,b,g 20.0
Mother smoking during pregnancy, %b 14.1
Smoke exposure in the home, %c 20.7
Pet exposure in the home, %c 46.7
Day care, %c 33.3
Wheeze, %c 68.9
Recurrent wheeze, %c,h 34.9
Dry cough at night, without cold, %c 40.4
Doctor-diagnosed asthma, %c 42.4
Doctor-diagnosed bronchitis, %c 52.8
Lower respiratory tract infection(s), %c,i 56.9
Eczema, %c 23.3
Asthma medication, %e,j 100
Inhaled/oral b2-agonists 82.4
Inhaled corticosteroids 41.8
Parasympathicolytics 40.0
Oral corticosteroids, %e 1.8
Antibiotics, %e 58.2
Other allergy medication, %e,k 50.9
a Data collected from questionnaires at the time of
pregnancy.
b Data collected from questionnaires at the age of 3 months.
c Data collected from questionnaires at the age of 1 year.
d Data collected from questionnaires at the age of 2 years.
e Data collected from the community pharmacy at the age of 4
years.
f Educational level: lowZ primary, lower vocational and
lower general; intermediateZ senior high school and interme-
diate vocational; and highZ higher vocational an university.
g Father or mother or both reported to have (had) asthma.
h Recurrent wheeze: 4 episodes wheeze.
i Lower respiratory tract infections: bronchitis, pneumonia
and pertussis.
j Due to our selection criteria the use of asthma medication
within the study population is 100%.
k Nasal antiallergics, systemic antihistamines, topical cortico-
steroids and antiallergic eye preparations.
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hazard ratios and 95% confidence intervals (CI) for discon-
tinuation of asthma medication use. The hazard ratio is the
effect of a variable on the hazard or risk of an event. In our
study the hazard ratio is the ratio of the rates at which
children are discontinuing asthma medication in the two
compared groups. In terms of interpretation, a hazard ratio
of 0.5 for boys would mean that at any point in time half as
many boys are discontinuing asthma medication propor-
tionally compared to girls. One has to keep in mind that
a variable with a low hazard ratio gives proportional a low
likelihood of discontinuation; such a variable is, therefore,
a strong predictor of persistence of treatment.
The following possible determinants of continuation of
medication use were investigated, representing patient
characteristics (gender, educational level of the parents),
severity of symptoms (doctor-diagnosed asthma, prescrib-
ing of inhaled corticosteroids, antibiotic use), familial
predisposition (allergic status of family members, eczema
of the child, use of other allergy medication) and environ-
mental influences (smoke exposure, pet exposure, day
care). Because doctor-diagnosed asthma and prescribing
of inhaled corticosteroids are expected to be related, an
interaction term is added for these two variables. Statis-
tical analyses were performed using SAS, version 9.1 (SAS
Institute, Cary, NC).
Results
General characteristics of the study population of 165
children who started using asthma medication in their first
year of life are shown in Table 1. Male gender was predom-
inant, with 69.7% boys in our study population. More than
half (56%) of the study population had at least one parent
with reported atopy (not shown in Table 1) and in 13%
both parents were atopic. The most commonly used asthma
medications were b2-agonists, prescribed to more than 80%
of the study population and use of inhaled corticosteroids
was seen in 40%. Almost 70% of the study population re-
ported wheezing in the first year of life of which 30% also
reported cough. Cough without wheeze was reported by
11% of the study population. The majority (57.6%) did not
have parental-reported doctor-diagnosed asthma in the
year asthma medication use was initiated.
Overall persistence of asthma medication use was low,
falling below 15% after three years of follow-up (Fig. 1).
Since 41.2% of the study population received a single pre-
scription for asthma medication, a steep fall in persistence
can be observed after approximately three months of treat-
ment. After these three months, a steady decline in persis-
tence was seen, becoming less steep around 16 months of
follow-up and reaching the level of 10.3% at the end of
follow-up.
Results from the univariate Cox regression analyses are
shown in Table 2. Since the hazard ratios are for discontin-
uation of asthma medication, hazard ratios below 1.0 imply
a higher persistence of asthma medication use. Most
characteristics, including an allergic father, the use of anti-
biotics, eczema and pet exposure were not related to
continuing use of asthma medication. Doctor-diagnosed
asthma, prescribed inhaled corticosteroids and the allergic
status of the mother were significantly associated withpersistent use of asthma medication. After adjusting for
the other significant variables and gender (see Table 3)
only doctor-diagnosed asthma and use of inhaled cortico-
steroids remain significantly associated. Children with doc-
tor-diagnosed asthma within the 1st year of life were 1.6
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Figure 1 Persistence of asthma medication use within the
study population: children receiving asthma medication in
the 1st year of life.
Table 3 Multivariate analyses of discontinuation of
asthma medication use in relation to patient characteristics.
95% CI for the HRadj
HRadj Lower Upper
Sex, boys 0.75 0.52 1.08
Doctor-diagnosed asthma 0.64a 0.45 0.91
Prescribed ICS 0.59a 0.40 0.86
Allergic mother 0.82 0.56 1.20
Definition of abbreviations: CIZ confidence interval;
HRadjZ the hazard ratio of the variable adjusted for all other
variables in the model; and ICSZ inhaled corticosteroids.
a Significant values p< 0.05.
Persistence of asthma medication use 1449times more likely (hazard ratio of discontinuationZ 0.64)
to continue asthma medication than children without such
a diagnosis. The strongest determinant of persistence of
use was a prescription for inhaled corticosteroids in the first
year of life, with a highly significant hazard ratio of discon-
tinuation of 0.59, rendering children using inhaled cortico-
steroids almost two times more likely to continue
treatment than children not using these drugs. No interac-
tion was found between the variables doctor-diagnosed
asthma and inhaled corticosteroid use.
Repeating the multivariate Cox regression, including
three dummy variables for the possible combinations of
the variables doctor-diagnosed asthma and inhaled corti-
costeroid use, rendered a significant adjusted hazard ratioTable 2 Univariate analyses of discontinuation of asthma
medication use in relation to patient characteristics.
95% CI for the HRcrude
HRcrude Lower Upper
Sex, boys 0.74 0.52 1.04
Mother’s educational level 1.03 0.83 1.27
Father’s educational level 0.94 0.76 1.16
Doctor-diagnosed asthma 0.56a 0.38 0.76
Prescribed ICS 0.52a 0.37 0.73
Antibiotics 0.87 0.62 1.20
Allergic mother 0.67a 0.47 0.96
Allergic father 1.12 0.80 1.57
Allergic sibling(s) 0.82 0.58 1.16
Parental asthma 0.71 0.47 1.08
Eczema 1.08 0.96 1.23
Allergy medication 0.87 0.63 1.20
Smoke exposure
in the home
1.17 0.99 1.38
Pet exposure
in the home
0.99 0.72 1.37
Day care 1.16 0.83 1.63
Definition of abbreviations: CIZ confidence interval; HRZ
hazard ratio; and ICSZ inhaled corticosteroids.
a Significant values p< 0.05.of discontinuation of 0.34 (95% CI: 0.25e0.63) for the group
of children with both a diagnosis of asthma and use of
inhaled corticosteroids. The difference in persistence
between children with both doctor-diagnosed asthma and
a prescription for inhaled corticosteroids and children
without both, is visualized by a KaplaneMeier curve in
Fig. 2. The main difference in persistence between the
groups was due to a difference in discontinuation after
the first prescription. After this steep fall, the declining
trend runs parallel between the compared groups.
Discussion
The study described here shows that 58.8% of children
initiating asthma treatment before the age of one, continue
medication use after the first prescription and only 10.3% is
persistent after three years of follow-up. Children with
doctor-diagnosed asthma and users of inhaled corticoste-
roids in the first year of life were 1.6e1.7 times more likely
to continue using asthma medication. When both diagnosed
with asthma and receiving inhaled corticosteroids, children
were three times more likely to continue until the age of 3.
No other measures were significantly associated with
persistence of asthma medication use.
Our results show that most of the time a trial of
asthma medication in very young children does not leadDashed line = asthma diagnosis + ICS use
Solid line = no asthma diagnosis, no ICS use
Log-rank p-value < 0.001
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Figure 2 Difference in persistence between children with
both an asthma diagnosis and a prescription for inhaled corti-
costeroids (ICS) and children without both diagnosis and ICS
in the first year of life.
1450 M.G. Zuidgeest et al.to regular asthma medication use. Children who do
become persistent asthma medication users could not be
identified by objective measures that can be determined
at start of therapy. Only the ‘physician-decided’ mea-
sures, doctor-diagnosed asthma and prescribing of inhaled
corticosteroids are associated with persistent asthma
medication use.
The low persistence found in our study is consistent with
the findings from previous studies that no valid criteria
exist to prospectively identify children who will develop
asthma within a group of wheezing children.1,2,18e20 More-
over, a great proportion of those who wheezed in their first
years of life did so for other reasons than asthma.2e6
However, other studies did find certain factors to be
associated with persistent wheeze and asthma later in life,
including early allergic sensitization,1,9,18,21,22 atopic dis-
ease (such as rhinitis, eczema), eosinophilia,19,22,23 female
sex,21 tobacco smoke exposure,21,22 a family history of
asthma,1,9,19,22e25early and/or severe wheezing.18,19,25
Other characteristics, including pet or farm animal expo-
sure,18 day care attendance or having older siblings18,26
and house-dust endotoxine18 might reduce the risk of
asthma. This association is not reflected in an association
with persistent asthma medication use. Our results show
that demographic characteristics, familial predisposition
and environmental influences were not significantly associ-
ated with persistence of asthma medication use.
In contrast, we found that doctor-diagnosed asthma and
prescribing of inhaled corticosteroids were significantly
associated with persistence of asthma medication use. As
both these measures and the outcome, persistence of
asthma medication use, are not objective measures but
physician-based, care should be taken in interpreting these
results. It is not unlikely that physicians are more inclined
to continue medication use after diagnosing a child with
asthma or prescribing inhaled corticosteroids. Therefore, it
is important that physicians check the necessity of con-
tinuing medication on a regular basis. In addition, restrict-
ing treatment to the group of children with doctor-
diagnosed asthma and use of inhaled corticosteroids does
not necessarily lead to better targeting of asthma medica-
tion, since a diagnosis of asthma is very difficult to make
before the age of 5 and, if given, should be considered
a working diagnosis.11,27,28
However, the low percentage of persistence in our
study and the finding that one-third of the children in
our study population does not report wheezing in the year
that asthma medication is initiated raises the question
whether overtreatment occurs, as has been reported in
previous studies.1,2,13,23,29,30 Especially since recent
evidence suggests that early inhaled corticosteroid treat-
ment has no effect on the natural history of asthma or
wheeze later in childhood and that the beneficial effect
during episodes of wheezing in preschool children is small
to none existent.20,31,32 Another study found no relation
between responses to inhaled bronchodilators in infancy
and asthma later in life, concluding that the presence or
absence of a response to bronchodilators in early life
cannot be used as a predictor of asthma.33
The current study has some limitations. First, we only
have information on medication use for the first four years
of life, hence the maximum follow-up of three years afterstart of asthma therapy. We do realize that the diagnostic
and treatment problems do not disappear at the age of 4.
However, since already very few children remain persistent
user after these three years we do not feel that the insight
into persistent asthma medication use in this population
would be much greater if we were able to add more years
of follow-up. Second, in this study we cannot determine
whether the persistence or discontinuation of medication is
a just action. About one-third of all children discontinuing
medication reported asthmatic symptoms in the year after
their medication was discontinued (data not shown). This
could imply undertreatment, especially since a quarter of
non-persistent children resumes medication use in year 4.
Third, parental-reported doctor-diagnosed asthma might
not be the true reflection of asthmatics. This has been
shown to differ substantially from a diagnosis of asthma
derived from the GPs clinical records in the sense that self-
reported asthma renders many more ‘asthmatics’ than do
the GP’s records.34
In conclusion, we show that a treatment trial in most
cases does not lead to regular use of asthma medication.
Only 58.8% of children continue medication use after the
initial prescription. With a three-year persistence of only
10.3% and the conflicting evidence on the benefit and
diagnostic value of not only trials of inhaled corticoste-
roids,20,31,32,35,36 but also b2-agonists37 and anticholiner-
gics38 in children suffering from (transient) wheeze, there
might be room for improvement in prescribing practice. It
is important to identify which children should or should
not be receiving asthma medication. However, our data
showed that no objective measures, including a family
history of asthma, eczema and smoke exposure, are associ-
ated with persistence of asthma medication use. These
findings stress the need for objective tools to diagnose
asthma at a young age.
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